Summary
The metabolic and haemodynamic effects of three intravenous doses (0.5, 1.0 and 4.0 mg) of prenalterol, a selective β1-adrenoceptor agonist, were studied in 10 healthy male subjects. Plasma levels of prenalterol during the experiments were related to the haemodynamic effects. Prenalterol induced a dose-dependent increase in systolic blood pressure and heart rate. The maximal effects amounted to about 30 mm Hg and 15 beats/min, respectively, after the highest dose (4.0 mg). The diastolic blood pressure fell by a maximum of about 15 mm Hg. The effect of prenalterol on systolic blood pressure and heart rate persisted for about 3 h after the end of the last infusion, whereas that on diastolic blood pressure only lasted for 60 min. Compared with placebo, there was a moderate increase in plasma FFA and glycerol. A small rise in insulin level was also recorded, but no significant change was seen in other metabolic variables — triglycerides, glucose, lactate, pyruvate. Serum potassium tended to decrease and serum sodium was unchanged. The initial distribution of prenalterol was rapid (half-life 7 min) and the overall elimination rate corresponded to a plasma half-life of 2 h. A linear relationship was found between the plasma level of prenalterol and its effects on systolic blood pressure and heart rate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Åblad, B., Börjesson, I., Carlsson, E., Johnsson, G.: Effects of metoprolol and propranolol on some metabolic responses to catecholamines in the anaethetized dog. Acta Pharmacol. Toxicol.36, Suppl. V, 85–95 (1975)
Antonis, A., Clark, M., Pilkington, T. R. E.: A semiautomated fluorimetric method for the enzymatic determination of pyruvate, lactate, acetoacetate, and β-hydroxybutyrate levels in plasma. J. Lab. Clin. Med.68, 2, 340–356 (1966)
Arnold, A.: Differentiation of receptors activated by catecholamine-III. Farmaco Ed. Sci.27, 79–100 (1972)
Arnold, A., McAuliff, J. P., Colella, D. F., O'Connor, W. V., Brown, T. G.: The β2 receptor mediated glycogenolytic responses to catecholamines in the dog. Arch. Intern. Pharmacodyn.170, 451 (1968)
Attman, P. O., Aurell, M., Johnsson, G.: Effects of metoprolol and prpranolol on furosemide-stimulated renin release in healthy subjects. Eur. J. Clin. Pharmacol.8, 201–204 (1975)
Berglund, G., Andersson, O., Larsson, O., Wilhelmsen, L.: Antihypertensive effect and side-effects of bendroflumethiazide and propranolol. Acta Med. Scand.199, 499–506 (1976)
Carlsson, E., Dahlöf, C.-G., Hedberg, A.: Differentiation of cardiac chronotropic and inotropic effects of β-adrenoceptor agonists. Naunyn-Schmiedeberg's Arch. Pharmacol.300, 101–105 (1977)
Davidson, M. B., Karjala, R.: Simplified fluorometric method for the determination of plasma glycerol. J. Lipid Res.11, 609–612 (1970)
Duncombe, W. G.: The colorimetric micro-determination of non-esterified fatty acids in plasma. Clin. Chim. Acta,9, 122–125 (1964)
Johnsson, G., Jordö, L., Lundborg, P., Rönn, O., Welin-Fogelberg, I., Wikstrand, J.: Haemodynamic and tolerance studies in man of a new, orally active, selective β1-adrenoceptor agonist H 80/62. Eur. J. Clin. Pharmacol.13, 163–170 (1978)
Knaus, M., Pfister, B., Dubach, U. C., Imhof, P. R.: Humanpharmacology studies with a new, orally active stimulant of cardiac adrenergic β-receptors (C50,005/A-Ba). Am. Heart J.95, 602–610 (1978)
Leese, H. J., Bronk, J. R.: Automated fluorometric analysis of micromolar quantities of ATP, glucose, and lactic acid. Anal. Biochem.45, 211–221 (1972)
Porte, D. Jr.: Beta adrenergic stimulation of insulin release in man. Diabetes16, 150 (1967)
Rönn, O., Graffner, C., Johnsson, G., Jordö, L., Lundborg, P., Wikstrand, J.: Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man. Eur. J. Clin. Pharmacol.15, 9–13 (1979)
Ruderman, N. B., Toews, C. J., Shafrir, E.: Role of free fatty acids in glucose homeostasis. Arch. Intern. Med.123, 299–313 (1969)
Scott, D. H. T., Arthur, G. R., Boyes, R. N., Scott, D. B.: Cardiovascular effects of prenalterol (H 133/22) in normal man. Br. J. Pharmacol.7, 365–370 (1979)
Sedman, A. J., Wagner, J. G.: CSTRIP, a Fortran IV computer program for obtaining initial polyexponential parameter estimates. J. Pharm. Sci.65, 1006–1010 (1976)
Wahlefeld, W.: Triglycerides. Determination after enzymatic hydrolysis. In: Methods of Enzymatic Analysis. H. U. Bergmeyer, (ed.) 2nd English ed., p. 1831. (Transl. from 3rd German ed.), New York, Weinheim: Verlag Chemie, Academic Press 1974
Wang, P., Clausen, T.: Treatment of attacks in hyperkalaemic familial periodic paralysis by inhalation of salbutamol. Lancet1976/I, 221–226
William-Olsson, T., Fellenius, E., Smith, U., Björntorp, P.: Differences in metabolic responses to beta-adrenergic stimulation after propranolol or metoprolol administration. Acta Med. Scand.205, 201–206 (1979)
Wright, W. R., Rainwater, J. C., Tolle, L. D.: Glucose assay systems: Evaluation of a colorimetric hexokinase procedure. Clin. Chem.17, 10, 1010–1014 (1971)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rönn, O., Fellenius, E., Graffner, C. et al. Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, in man. Eur J Clin Pharmacol 17, 81–86 (1980). https://doi.org/10.1007/BF00562614
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00562614